Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 plus chemotherapy with or without Enlonstobart in first-line HER2-positive advanced or metastatic gastric cancer
CTR20254932Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab in gastric cancer (GC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Feb 2026; status: active.
02
Drugs
anbenitamab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on CTR20254932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254932.